Sionna Therapeutics (SION) – Investment Analysts’ Recent Ratings Changes

Sionna Therapeutics (NASDAQ: SION) has recently received a number of price target changes and ratings updates:

• 3/2/2026 – Sionna Therapeutics had its price target raised by Guggenheim from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 3/2/2026 – Sionna Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 3/2/2026 – Sionna Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.
• 2/25/2026 – Sionna Therapeutics was upgraded by Lifesci Capital to “strong-buy”.
• 2/24/2026 – Sionna Therapeutics is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
• 2/24/2026 – Sionna Therapeutics is now covered by Citizens Jmp. They set a “market outperform” rating and a $63.00 price target on the stock.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 33,356 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the transaction, the director owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This represents a 0.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Peter A. Thompson sold 33,356 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 382,368 shares of company stock worth $15,898,607. Insiders own 3.90% of the company’s stock.

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.